139
Participants
Start Date
February 28, 2007
Primary Completion Date
January 31, 2015
Study Completion Date
January 31, 2015
Cetuximab
5-fluorouracil
Pelvic irradiation
New York Oncology Hematology, P.C., Albany
Alliance Hematology Oncology PA, Westminster
Virginia Oncology Associates, Norfolk
Raleigh Regional Cancer Center, Beckley
Cancer Centers of North Carolina, Raleigh
Melbourne Internal Medicine Associates, Melbourne
Advanced Medical Specialties, Miami
Cancer Centers of Florida, P.A., Ocoee
Cancer Care & Hematology Specialists of Chicagoland, PC, Niles
St. Joseph Oncology, Inc., Saint Joseph
Missouri Cance Associates, Columbia
Kansas City Cancer Centers-Southwest, Overland Park
Lake Vista Cancer Center, Lewisville
Texas Cancer Center - Sherman, Sherman
Texas Cancer Center at Medical City, Dallas
Methodist Charlton Cancer Ctr., Dallas
Texas Oncology, P.A., Dallas
Paris Regional Cancer Center, Paris
Longview Cance Center, Longview
Tyler Cancer Center, Tyler
Texas Oncology, P.A., Fort Worth
Texas Cancer Center, Denton
Central Indiana Cancer Centers, Indianapolis
Texoma Cancer Center, Wichita Falls
Texas Oncology Cancer Care and Research, Waco
Texas Oncology Cancer Center-Sugar Land, Sugar Land
Texas Oncology, P.A., Webster
Mamie McFaddin Ward Cancer Center, Beaumont
HOAST - Medical Dr., San Antonio
Texas Oncology Cance Center, Austin
Texas Oncology - Amarillo, Amarillo
Allison Cancer Center, Midland
Texas Oncology-Odessa, Odessa
El Paso Cancer Treatment Ctr, El Paso
Oncology Associates D.B.A. Hematology Oncology Physicians & Extenders, Tucson
Comprehensive Cancer Centers of Nevada, Las Vegas
Willamette Valley Cancer Center, Eugene
Highline Medical Oncology, Burien
Northwest Cancer Specialists-Vancouver, Vancouver
Yakima Valley Mem Hosp/North Star Lodge, Yakima
Cancer Care Northwest-South, Spokane
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Eli Lilly and Company
INDUSTRY
US Oncology Research
INDUSTRY